AIM: To investigate the efficacy and toxicity of systemic chemotherapy in a retrospective study of patients with hepatocellular carcinoma (HCC) occurring in normal or fibrotic liver without cirrhosis. METHODS: Twenty-four patients with metastatic or locally advanced HCC in a normal or a fibrotic liver were given systemic chemotherapy (epirubicin, cisplatin and 5-fluorouracil or epirubicin, cisplatin and capecitabine regimens). Tumor response, time to progression, survival, and toxicity were evaluated. RESULTS: There were 7 women and 17 men, mean age 54 +/- 10 years; 18 patients had a normal liver and 6 had a fibrotic liver (F1/F2 on biopsy). Mean tumor size was 14 cm, 5 patients had portal vein thrombosis and 7 had metastasis. Patients received a median of 4 chemotherapy sessions. Overall tolerance was good. There were 5 partial responses (objective response rate = 22%), and tumor control rate was 52%. Second line surgical resection was possible in two patients. Median survival was 11 mo, and 1- and 2-year overall survival rates were 50% +/- 10% and 32% +/- 11%, respectively. CONCLUSION: In patients with HCC in a non-cirrhotic liver, chemotherapy was well tolerated and associated with an objective response rate of 22%, including two patients who underwent secondary surgical resection.
AIM: To investigate the efficacy and toxicity of systemic chemotherapy in a retrospective study of patients with hepatocellular carcinoma (HCC) occurring in normal or fibrotic liver without cirrhosis. METHODS: Twenty-four patients with metastatic or locally advanced HCC in a normal or a fibrotic liver were given systemic chemotherapy (epirubicin, cisplatin and 5-fluorouracil or epirubicin, cisplatin and capecitabine regimens). Tumor response, time to progression, survival, and toxicity were evaluated. RESULTS: There were 7 women and 17 men, mean age 54 +/- 10 years; 18 patients had a normal liver and 6 had a fibrotic liver (F1/F2 on biopsy). Mean tumor size was 14 cm, 5 patients had portal vein thrombosis and 7 had metastasis. Patients received a median of 4 chemotherapy sessions. Overall tolerance was good. There were 5 partial responses (objective response rate = 22%), and tumor control rate was 52%. Second line surgical resection was possible in two patients. Median survival was 11 mo, and 1- and 2-year overall survival rates were 50% +/- 10% and 32% +/- 11%, respectively. CONCLUSION: In patients with HCC in a non-cirrhotic liver, chemotherapy was well tolerated and associated with an objective response rate of 22%, including two patients who underwent secondary surgical resection.
Authors: D Pastorelli; G Cartei; F Zustovich; F Marchese; G Artioli; S Zovato; S Binato; R Ceravolo; S Cingarlini; F Salmaso; M Mattiazzi; C Sanavio; F Farinati; G Zanus; U Cillo Journal: Ann Oncol Date: 2006-05 Impact factor: 32.976
Authors: W Yeo; K C Lam; B Zee; P S K Chan; F K F Mo; W M Ho; W L Wong; T W T Leung; A T C Chan; B Ma; T S K Mok; P J Johnson Journal: Ann Oncol Date: 2004-11 Impact factor: 32.976
Authors: Winnie Yeo; Tony S Mok; Benny Zee; Thomas W T Leung; Paul B S Lai; Wan Y Lau; Jane Koh; Frankie K F Mo; Simon C H Yu; Anthony T Chan; Pun Hui; Brigette Ma; Kwok C Lam; Wing M Ho; Herman T Wong; Amanda Tang; Philip J Johnson Journal: J Natl Cancer Inst Date: 2005-10-19 Impact factor: 13.506
Authors: A Bamias; M E Hill; D Cunningham; A R Norman; F Y Ahmed; A Webb; M Watson; A S Hill; M C Nicolson; M E O'Brien; T C Evans; V Nicolson Journal: Cancer Date: 1996-05-15 Impact factor: 6.860
Authors: Robert G Gish; Camillo Porta; Lucian Lazar; Paul Ruff; Ronald Feld; Adina Croitoru; Lynn Feun; Krzysztof Jeziorski; John Leighton; José Gallo; Gerard T Kennealey Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Se Hoon Park; Yuna Lee; Sang Hoon Han; So Young Kwon; Oh Sang Kwon; Sun Suk Kim; Ju Hyun Kim; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee Journal: BMC Cancer Date: 2006-01-05 Impact factor: 4.430
Authors: T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech Journal: Z Gastroenterol Date: 2013-11-15 Impact factor: 2.000